Results 61 to 70 of about 9,749 (194)
Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens
, 2013 The use of basiliximab induction increased significantly in recent years based on its superior efficacy and excellent safety profile demonstrated in studies with cyclosporine-based immunosuppression.
Franco, Marcello Fabiano de [UNIFESP] +4 more
core +1 more source
Reacción anafiláctica fatal por Basiliximab
, 2015 El Basiliximab es un anticuerpo monoclonal ampliamente utilizado en trasplante renal para la inducción de inmunosupresión. Su introducción ha disminuido la incidencia de rechazo agudo en el primer año postrasplante renal pero no ha demostrado efectos
Fragale, Guillermo. +3 more
core +1 more source
CD25 appears non essential for human peripheral T(reg) maintenance in vivo. [PDF]
PLoS ONE, 2010 IL-2 has been reported to be critical for peripheral T(reg) survival in mouse models. Here, we examined T(reg) maintenance in a series of paediatric liver transplant recipients who received basiliximab, a therapeutic anti-CD25 monoclonal antibody.FoxP3 ...
Marie-Ghislaine de Goër de Herve +7 more
doaj +1 more source
MedComm, Volume 7, Issue 9, September 2026.This multicenter, real‐world study with a large sample size (i.e., vedolizumab for aGVHD refractory to steroid treatment, VAST study) was designed to identify the safety and efficacy of vedolizumab treatment in patients with steroid‐refractory gastrointestinal acute graft‐versus‐host disease (SR‐GI‐aGVHD). The overall response rates (ORR) on day 28 and
Leqing Cao +13 more
wiley +1 more source
Homogenous Cell Transplantation Trials in Parkinson's Disease: A Systematic Review and Meta‐Analysis
Movement Disorders Clinical Practice, Volume 13, Issue 9, Page 2093-2103, September 2026.Abstract Background The transplantation of homogenous cells has emerged as an investigational strategy for Parkinson's disease (PD), offering an alternative to symptomatic treatment. Objective We performed a systematic review and meta‐analysis to assess its clinical efficacy and safety.
Nolan Reinisch +4 more
wiley +1 more source
, 2001 BACKGROUND: A double-blind, placebo-controlled, randomized study was performed to assess whether immunoprophylaxis with basiliximab (Simulect) could reduce the incidence of acute rejection in kidney transplant recipients treated with cyclosporine (Neoral)
Ponticelli, C +15 more
core +1 more source
, 2022 We aimed to identify the characteristics of immune reconstitution (IR) in patients who recovered from steroid-refractory acute graft-versus-host disease (SR-aGVHD) after basiliximab treatment. A total of 179, 124, 80, and 92 patients were included in the
Jing-Zhi Wang (3722098) +15 more
core +1 more source
Organ Medicine, Volume 3, Issue 3, Page 139-147, September 2026.Serum galactose‐deficient IgA1 levels at 3 and 6 months predicted recurrent IgA nephropathy after kidney transplantation. Recipients without recurrence showed a rapid decline in galactose‐deficient IgA1 after transplantation. Early identification of recurrence risk provided a potential window for targeted post‐transplant intervention.
Ronghai Deng +10 more
wiley +1 more source
Effect of basiliximab on renal allograft rejection within 1 year after
, 2006 Basiliximab is widely used in clinical practice for initial immunosuppressive treatment of renal transplant recipients, seeking to reduce the incidence of acute rejection episodes without adverse events.
Kim, H +6 more
core +1 more source
Organ Medicine, Volume 3, Issue 3, Page 157-170, September 2026.Intestinal obstruction (IO) is an important but underexplored complication following simultaneous pancreas‐kidney transplantation (SPKT) and is associated with considerable morbidity and both clinical and economic burdens. In this single‐center cohort study, perioperative parameters, including demographic characteristics, surgical variables, and ...
Rongxin Chen +7 more
wiley +1 more source